Accueil

.

UMR754 IVPC "Viral Infections and Comparative Pathology"

In recent years, the circulation of infectious agents has increased significantly, along with the health risks potentially associated with them. The World Organisation for Animal Health (OMSA) highlights the threat that animal diseases pose to public health: 60% of human pathogens and 75% of emerging human pathogens originate from animals. These emerging, re-emerging, or endemic diseases highlight the importance of the animal–human or animal–vector–human interface in a context of globalized exchanges and environmental changes, suggesting that the control and management of these health risks can only be considered through a global and integrated approach.
The research conducted in our unit, UMR754 “Viral Infections and Comparative Pathology” (IVPC), therefore follows a One Health approach, which considers that human and animal health are interdependent and closely linked to the ecosystems in which they coexist.

article

20 November 2025

By: PYL

Reminder: PhD defense of Qilin Xin

Qilin Xin (aka Colin) from the iWays team will defend his Ph.D. thesis on Thursday, November 23, 2023 (University Claude Bernard Lyon 1, France) entitled “Link between molecular composition, ultrastructure, and infectivity of Germiston viruses (GERV) derived from mammalian and mosquito cell lines”. Venue, Amphi G1, 50 avenue Tony Garnier, 69007 Lyon
article

24 October 2024

By: PYL

NSs forms a filamentous E3 ligase to degrade host cell proteins

The iWays team collaborated with the laboratory of Ke Peng (Wuhan, China) to reveal that the NSs protein of Rift Valley fever virus coordinates the assembly of an E3 ligase to promote viral replication.

Anna-Bella FAILLOUX – Institut Pasteur, Paris – Mardi 02 Juillet – The treat of arboviral diseases: the chikungunya in the context of climate change

BUNYA team in Pint Of Science 2024 talking mosquito-borne viruses

The iWays team has been awarded a FRM Team 2024 grant for its project entitled "Rift Valley fever virus and its protein NSs as a novel model for studying amyloid aggregation", scheduled to last 3 years.